Matthias M. Meier
Basel, BS, Switzerland
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 30 publications
Oral iptacopan therapy in patients with C3 glomerulopathy: a randomised, double-blind, parallel group, multicentre, placebo-controlled, phase 3 study.
Journal: Lancet (London, England)
Published: February 28, 2025
Factor B as a therapeutic target for the treatment of complement-mediated diseases.
Journal: Frontiers in immunology
Published: December 02, 2024
Iptacopan Reduces Proteinuria and Stabilizes Kidney Function in C3 Glomerulopathy.
Journal: Kidney international reports
Published: September 26, 2024
Kidney Transplantation in Children and Adolescents With C3 Glomerulopathy or Immune Complex Membranoproliferative Glomerulonephritis: An International Survey of Current Practice.
Journal: Pediatric transplantation
Published: August 28, 2024
Developing Therapies for C3 Glomerulopathy: Report of the Kidney Health Initiative C3 Glomerulopathy Trial Endpoints Work Group.
Journal: Clinical journal of the American Society of Nephrology : CJASN
Published: June 03, 2024
Kidney transplantation in children and adolescents with C3 glomerulopathy or immune complex membranoproliferative glomerulonephritis: a real-world study within the CERTAIN research network.
Journal: Pediatric nephrology (Berlin, Germany)
Published: May 30, 2024
Iptacopan in Idiopathic Immune Complex-Mediated Membranoproliferative Glomerulonephritis: Protocol of the APPARENT Multicenter, Randomized Phase 3 Study.
Journal: Kidney international reports
Published: June 06, 2023
Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
Journal: Kidney international
Published: December 07, 2022
Long-Term Effects of Everolimus-Facilitated Tacrolimus Reduction in Living-Donor Liver Transplant Recipients with Hepatocellular Carcinoma.
Journal: Annals of transplantation
Published: November 22, 2022
Targeting the Alternative Complement Pathway With Iptacopan to Treat IgA Nephropathy: Design and Rationale of the APPLAUSE-IgAN Study.
Journal: Kidney international reports
Published: November 01, 2022
Predictive Value of Early Postoperative Course of Serum Cortisol After Transsphenoidal Surgery for Cushing's Disease.
Journal: Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association
Published: September 09, 2022
Alternative Complement Pathway Inhibition With Iptacopan for the Treatment of C3 Glomerulopathy-Study Design of the APPEAR-C3G Trial.
Journal: Kidney international reports
Published: March 23, 2022
Last Updated: 09/26/2026